All Activity

Advocates have long argued that marijuana legalization is a superior alternative to criminalization. But while that sentiment prevails with the public and a growing number of lammakers, a leading drug policy reform group says it’s nonetheless important to recognize and address potential public health impacts of consumer trends in state-regulated markets—including the rise of high-potency THC products. Prohibitionists have been quick to seize upon reports of adverse health incidents associated with products engineered to maximize THC, whether it’s naturally produced delta-9 THC in marijuana, synthetically manufactured delta-8 THC in hemp or any of the numerous other iterations of the intoxicating cannabinoid. But rather than revert to banning such products outright, officials should prioritize targeted regulations to balance public health and consumer choice, the pro-legalization Drug Policy Alliance (DPA) said in a new report titled “High-THC Marijuana: Protecting Public Health In A Changing Market.” “As product potency rises, so do important public health questions about safety, youth access, and consumer transparency,” it says, adding that DPA’s position is that “legalization must be paired with thoughtful, evidence-based regulation that protects health, enhances safety, and reduces harm.” The organization isn’t necessarily arguing that high-THC cannabis products present an imminent public health threat, pointing to the “mixed body of research” on the potential negative health impacts such as the development of cannabis use disorder, anxiety and other mental health conditions. But there is a need to expand research into the issue and inform public policy, particularly as it concerns youth use and access, DPA said. For some patients, higher concentrations of THC can “help manage pain and other medical conditions,” the report said, so regulations should “consider medical exemptions or alternate provisions to accommodate these patients’ needs.” At the same time, one of the group’s recommendations is to ensure that legal markets offer a diversified array of products that includes low-THC options for patients and consumers. Overall, one of DPA’s top recommendations is to create a “unified regulatory framework for all cannabinoids (including hemp-derived products like delta-8 THC) with consistent standards for testing, labeling, age restrictions, and consumer protections.” Other proposals essentially follow the same line of policy thinking that reform advocates have long pushed for as an alternative to criminalizing cannabis. That is, they want to see research (including opportunities for federal studies) expanded, restrictions such as age-gating enforced to mitigate youth access and tax revenue allocations that support mental health treatment and other public health initiatives. There should also be improvements in “consumer education and product transparency with standardized serving sizes, clear THC content labeling, prominent warning labels, retail education materials, and training for dispensary staff,” the report says. Because there may be health impacts associated with high-THC cannabis, policymakers should additionally consider potential alternatives to blanket bans that still aim to steer the market away from becoming oversaturated with such products. That could include setting prices based in part on THC potency, while also requiring low-THC product availability in the regulated market. Although the science and health impacts of high-THC cannabis is still being studied, one thing is undeniable: There has been a steady rise in the marketing and sale of such products as the state legalization movement has expanded and businesses have responded to consumer demand. DPA’s report is meant to respond to that reality, without ceding the issue to anti-legalization interests that have used fears about the use of these highly potent products to promote prohibitionist policies. Cat Packer, DPA’s director of legal regulation, said in a Q&A about the THC potency issue that “no one should be arrested for marijuana and policies cannot return to bringing back harmful and ineffective criminalization tactics.” “Legal regulation must address the ongoing harms of criminalization that impede on someone’s livelihood and basic needs,” she said. “At minimum, clearing records for all past marijuana arrests and convictions. Not having a criminal record removes barriers to economic opportunities and housing access. Ending criminalization also stops law enforcement from targeting certain communities.” The DPA report concludes by reiterating that high-THC marijuana products “pose complex regulatory challenges that demand a balanced, evidence-based response.” “As product potency increases and markets evolve, policy must keep pace. Failing to modernize regulatory frameworks poses threats to public health, particularly for youth and individuals vulnerable to mental and physical health issues and substance use disorders,” it says. “By aligning hemp and marijuana regulations, strengthening research and data collection, improving product transparency, and implementing safeguards for high-THC products, policymakers can reduce preventable harms while preserving access for adult consumers and medical patients,” it continues. “Public education, responsible retail practices, and reinvestment of tax revenue into treatment and prevention are critical to regulation that balances commercial interests with public health.” Aligning hemp and marijuana rules has become all the more urgently needed as the federal definition of hemp is set to fundamentally change later this year, with a significantly more restrictive threshold for THC to be considered legal hemp. Industry stakeholders say that policy change, which is set to take effect in November under a broader agriculture law President Donald Trump enacted last year, threatens to effectively eradicate the consumable cannabinoid market. “A strong regulatory framework that is grounded in evidence, health, and consumer protections offers the clearest path forward,” DPA said. “Policymakers should heed these recommendations to mitigate risks, promote informed decision-making, and ensure market innovations do not outpace health protections.” Meanwhile, amid shifting state and federal cannabis policies, the White House has scheduled several meetings with cannabis industry and research stakeholders to discuss a proposed enforcement policy for non-intoxicating CBD products. Also in the background, advocates and stakeholders are also eagerly awaiting the finalization of a rule to move marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA). Trump signed an executive order in December directing the attorney general to expeditiously complete that process—which would help streamline cannabis research while allowing state-licensed businesses to take federal tax deductions—but that remains pending. The post Drug Reform Group Lays Out Options To Address High-THC Marijuana’s Risks Without Returning To Criminalization appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

thank you for creating this safe space for women to share their stories - it's so important that we lift each other up and know we're not alone. i appreciate the work you're doing at cookie clicker 2 to support this community.

“This is a careful bill for people, our veterans and first responders, who have carried extraordinary burdens.” By Rebecca Rivas, Missouri Independent After four years of trying, the Missouri House passed legislation Thursday that would require the state to conduct a study on using psilocybin—also known as “magic mushrooms”—and other alternative therapies to treat depression, substance use or as part end-of-life care. Veterans and first-responders would be able to possess the psychedelic if they’re enrolled in a study, where it would be administered by a facilitator. Despite overwhelming support for the idea in past years, Thursday marks the first time the House has sent the bill on to the Senate, with a vote of 137 to 11. Lawmakers amended the legislation last week to include ibogaine, a powerful psychoactive compound derived from an African shrub that’s used to treat addiction, PTSD and traumatic brain injury. Republican state Rep. Renee Reuter of Imperial gave an emotional account of her husband’s struggles with post-traumatic stress disorder during House debate last week. After serving overseas in the U.S. Army in 1993, her husband’s PTSD has “enticed him to do certain things” that have destroyed their marriage and lives. “When he left in 1993 I told my husband, ‘You do whatever you have to do, but come home,’” Reuter said. “In ‘94 when my husband came home, he didn’t come all the way home.” Her son has also been deployed three times overseas and experiences PTSD as well. “Let’s do this for those men and women,” she said. “Let’s give them whatever it is that we need to give them to help them and their families continue to live and be productive members of society.” While the bill was originally focused on helping veterans, Republican state Rep. Matthew Overcast pushed to expand the bill to also include first responders. In 2020, Overcast worked for a company that handled staffing for nurses in New York hospitals, and he saw how the pandemic impacted the hospital workers. “I can tell you from walking through some of those nursing wards,” said Overcast, who is also a veteran. “There was more death that they saw in those few months when it first hit, than even some of our own soldiers have seen in a war.” This bill requires the Missouri Department of Mental Health to provide grants totaling $2 million for the research on alternative therapies, subject to lawmakers approving the appropriation. The state would collaborate on the study with a Missouri university hospital or medical center operated by the U.S. Department of Veterans Affairs in Missouri. The focus of the treatment is on veterans suffering from post-traumatic stress disorder, depression, substance use disorders, or for those who require end-of-life care. The suicide rate among veterans in Missouri is nearly double the state rate and one of the highest in the country. “This is a careful bill for people, our veterans and first responders, who have carried extraordinary burdens that most of us could only be we can’t really even imagine,” Overcast said, “and they endured significant trauma, not only in service to our communities, but to our country as well. It is measured, it is compassionate and it is accountable.” The bill’s sponsor, Republican state Rep. Richard West of Wentzville, said as a former police officer, he was skeptical of alternative therapies at first. But he’s read the study results and believes states should support furthering the research. That includes studies done by psychiatry researchers at Washington University School of Medicine in St. Louis, who were the first in Missouri to give a legal dose of psilocybin in 2019. They have been using a brain-imaging technique to learn how psilocybin affects certain networks in the brain. Republican State Rep. Dave Griffith of Jefferson City, a veteran who has supported the measure for several years, said it was appropriate to add first responders as eligible participants. “I think the most important thing about this bill is going to be done under a controlled atmosphere,” Griffith said, before the House passed the bill Thursday. “There needs to be safeguards put in place for them. [West] set up all those guardrails for us, so I’d ask somebody to support this bill.” This story was first published by Missouri Independent. The post Missouri Lawmakers Pass Bill Supporting Psychedelics Research To Aid Military Veterans And First Responders appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Congressional lawmakers were recently presented with a unique argument in favor of expanding therapeutic access to cannabis and rescheduling marijuana under federal law: Doing so could mitigate threats associated with Chinese Community Party (CCP) operatives. At a hearing before the House Small Business Committee last month, members took expert testimony on a variety of challenges linked to CCP, including intellectual property theft, foreign investments and vulnerabilities in the supply chain that impact small U.S. companies. The hearing—titled “Defending Main Street: Combating CCP Threats to America’s Small Businesses” Summary”—involved testimony from Sean Murphy, founder of the nonprofit organization Kompassion that focuses on palliative care and rare diseases afflicting children. Murphy said his personal experience raising a child with a severe health condition as well as volunteering in veterans hospices informed his advocacy for cannabinoid research and reform. That includes a proposal to move marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA) to “unlock research and healing, especially for rare diseases,” he said. Rescheduling wouldn’t federally legalize cannabis, but it would remove certain Schedule I research barriers, while benefitting state-licensed marijuana businesses by allowing them to take federal tax deductions they’re currently barred from under an Internal Revenue Service (IRS) code known as 280E. The incremental change “will be a monumental movement in research and development of cures,” Murphy said in a written testimony submitted to the committee. And while marijuana remains Schedule I, President Donald Trump signed an executive order in December directing the attorney general to quickly finalize its reclassification under a process that was initiated under the Biden administration. As part of his testimony for the committee hearing, Murphy also included policy recommendations that he argued would help address lawmakers’ concerns by empowering U.S. entrepreneurs and small business owners in healthcare, while generally expanding their access to capital. One of the recommendations involves targeted funding for energetic medicine, palliative care and cannabinoid research through the Advanced Research Projects Agency for Health (ARPA-H) under the U.S. Department of Health and Human Services (HHS). With funding for ARPA-H currently at $1.5 billion for the 2026 fiscal year, a portion should be side aside to “explicitly” support initiatives such as cannabinoid research, “including new therapeutic pathways made possible by marijuana’s rescheduling from Schedule I to Schedule III,” the testimony says. “All mammals possess an endocannabinoid system (ESC) that plays a central role in inflammation reduction and homeostasis; targeted research in this area would unlock breakthrough whole-health approaches that treat the body’s nervous and endocannabinoid system, while supporting veteran and family care, all while keeping IP and data 100 percent secure from foreign exploitation,” it says. Cannabis policy also intersected with a congressional hearing focused on foreign threats last year, when a GOP-led House committee looked at challenges associated with Chinese criminal organizations behind large-scale illicit marijuana grows. Leveraging the increasing attention to the issue, the prohibitionist group Smart Approaches to Marijuana (SAM) put out an ad in July arguing that if President Donald Trump moved forward with a pending cannabis rescheduling proposal, it would empower Chinese cartels. In 2023, a major marijuana lobbying firm apologized after sending a letter to Senate committee leadership concerning a bipartisan cannabis banking bill that contained “inappropriate” references to investments from China in a “misguided attempt” to push for amendments expanding the legislation. The post Marijuana Rescheduling Could ‘Unlock Research’ To Treat Rare Diseases, Father Of Terminally Ill Child Tells Congressional Committee appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

FBI memo on marijuana investments; Another Medicare hemp coverage rule; NC governor pushes legalization; HI cannabis resolutions Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… BREAKING: Journalism is often consumed for free, but costs money to produce! While this newsletter is proudly sent without cost to you, our ability to send it each day depends on the financial support of readers who can afford to give it. So if you’ve got a few dollars to spare each month and believe in the work we do, please consider joining us on Patreon today. https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW President Donald Trump is proposing that Congress continue a rider protecting state medical cannabis laws from federal interference for the first time after suggesting its deletion in prior budget requests—but he is also asking lawmakers to keep blocking Washington, D.C. from legalizing recreational marijuana sales The Federal Bureau of Investigation declassified a guidance memo blocking agents from investing in or working at marijuana companies but allowing involvement with hemp and CBD businesses—except if their packaging depicts a cannabis leaf, which is considered “promotion of marijuana.” The Centers for Medicare & Medicaid Services filed a Federal Register notice finalizing a rule to allow coverage of some hemp products like hulled seed, seed protein powder and seed oil as specialized benefits through Medicare Advantage plans. North Carolina Gov. Josh Stein (D) is stepping up the push to legalize marijuana after the Advisory Council on Cannabis he appointed issued an interim report recommending the state move away from a criminalization-based approach and toward a system of “robust” regulations providing legal access to THC products. The Louisiana Senate Health and Welfare Committee approved a bill to allow patients with terminal and irreversible conditions to use medical marijuana in hospitals, subject to certain limitations. The Hawaii Senate Judiciary Committee approved resolutions calling on Congress to federally legalize marijuana, support state efforts to clear people’s conviction records and take steps to facilitate access to banking services for companies in the cannabis industry. Missouri lawmakers sent Gov. Mike Kehoe (R) a bill to ban intoxicating hemp products, protect marijuana consumers’ privacy and recognize cannabis industry workers’ right to unionize. / FEDERAL Rep. Jim Baird (R-IN) expressed his concerns about the pending federal recriminalization of hemp products at a House Appropriations Subcommittee Agriculture, Rural Development, Food and Drug Administration and Related Agencies hearing. / STATES Former New Jersey Gov. Chris Christie (R) discussed his opposition to legalizing marijuana. Delaware regulators filed proposed changes to marijuana product rules. Missouri regulators filed proposed rules to establish marijuana research facilities. Minnesota regulators published guidance about on-site cannabis consumption. New York’s new top marijuana regulator discussed his plans for overseeing the legal industry. Massachusetts regulators are investigating a whistleblower complaint against a marijuana business. New York cannabis regulators posted an updated form for reporting incidents or complaints. The Illinois Medical Cannabis Advisory Board will meet on Monday. The Georgia Access to Medical Cannabis Commission will meet on Wednesday. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / LOCAL Los Angeles, California regulators sent an update about various cannabis issues. / INTERNATIONAL Saint Kitts and Nevis Prime Minister Terrance Drew spoke about efforts to implement cannabis reform in a “careful and measured” way. Nepal local governments are taking steps to allow cannabis cultivation. / SCIENCE & HEALTH A study found that “Christian participants reported the most favorable views toward both medical and recreational cannabis, followed by Jewish respondents, while Muslim and Druze participants expressed more conservative attitudes.” A study found that “individuals purchased and consumed cannabis regardless of legal status and legal status was not significantly associated with harm or benefit rating, controlling for demographic and use data” and that “individuals appear more likely to purchase through legal means, if available.” / BUSINESS Curaleaf Holdings, Inc.’s chief legal officer extended an existing automatic securities disposition plan. Village Farms International, Inc.’s chief financial officer is leaving the post while remaining an employee of the company. / CULTURE Scarlett Johansson talked about seeing Cypress Hill smoke a very large blunt at the first concert she ever attended. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post Trump puts medical cannabis protections in budget (Newsletter: April 6, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Interesting perspective on postpartum depression. While I appreciate the author's candidness, it's crucial to consult healthcare professionals. Individual experiences vary drastically. Perhaps incorporating discussion of professional therapy alongside alternative treatments, and risks, would offer a more balanced view. It reminds me of the focus and calm some find when playing Drift Boss – a temporary escape doesn't replace comprehensive care.

Wow, that's a powerful story! It's disheartening to hear about the lack of support and the reliance on potentially harmful medications like Oxycontin for postpartum depression. It's interesting to consider alternative approaches. It sounds like Samantha found something that worked for her, and it's great she's sharing her experience. It reminds me of simpler times, relaxing and just managing something simple, maybe like playing Papa's Freezeria. Every mom deserves access to options that truly help them, with open discussion and less stigma. Thanks for sharing!

A Louisiana Senate panel has advanced a bill to allow patients with terminal and irreversible conditions to use medical marijuana in hospitals. The Senate Health and Welfare Committee approved the legislation, SB 270 from Sen. Katrina Jackson-Andrews (D), with amendments, in a voice vote on Wednesday. “This bill was brought at the request of constituents who believe that therapeutic medical marijuana, which is already legal in this state, should be offered in hospitals when patients are terminally ill or otherwise in need the comfort of this medicine,” Jackson-Andrews said ahead of the vote. Under the proposal, hospitals would have to create written guidelines allowing covered patients to consume medical cannabis on-site in forms other than smoking or vaping. Under an amendment adopted by the panel, emergency or outpatient departments would be exempted from the policy. The revised legislation also clarifies that patients and primary caregivers are responsible for acquiring and administering medical marijuana, which must be “stored securely at all times in a locked container provided by the patient.” Health care professionals and staff would be prohibited from “administering, storing, retrieving, or assisting the patient with the medical marijuana,” the text says. The amendment, which the sponsor worked on with help from the Louisiana Hospital Association, also allows hospitals to opt out of the policy if federal officials take action against any healthcare facility in the state over medical cannabis use, rather than only allowing those that were specifically targeted to stop complying. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile in Louisiana, the Senate Health and Welfare Committee last week approved a bill to create a psychedelic-assisted therapy pilot program, using opioid settlement dollars to fund clinical trials aimed at developing alternative treatments such as psilocybin and ibogaine. Lawmakers are also considering a bill to create an adult-use marijuana legalization pilot program in the state to determine whether the reform should eventually be expanded and permanently codified. The post Louisiana Senators Approve Bill To Allow Medical Marijuana Use In Hospitals For Terminally Ill Patients appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

You there, this is really good post here. Thanks for taking the time to post such valuable information. Quality content is what always gets the visitors coming. live casino online

Your work is truly appreciated round the clock and the globe. It is incredibly a comprehensive and helpful blog. live casino

i love reading this article so beautiful!!great job! bolahit daftar

Positive site, where did u come up with the information on this posting?I have read a few of the articles on your website now, and I really like your style. Thanks a million and please keep up the effective work. situs kebun4d

The legislation also has provisions to protect marijuana consumers’ privacy and cannabis workers’ right to unionize. By Rebecca Rivas, Missouri Independent A bill now heading to Missouri Gov. Mike Kehoe’s (R) desk would take all intoxicating hemp products off the shelves starting November 12—including THC seltzers currently sold in bars and grocery stores—aligning state law with an upcoming federal ban. If Congress reverses course and decides to allow the sale of these products, Missouri would only permit them to be sold in licensed marijuana dispensaries. And if Congress chooses to delay the ban for a couple years, Missouri would still ban all products, except for the sale of intoxicating beverages in dispensaries. The House passed a bill sponsored by Republican state Rep. Dave Hinman of O’Fallon with a vote of 126 to 23. It passed the Senate Tuesday night and now heads to the governor for his signature or veto. The bill also includes provisions to protect marijuana consumer privacy and cannabis workers’ right to organize, which were amendments state senators added late Tuesday evening. Hinman’s legislation was one of the first bills to get House approval this year. He previously told The Independent the legislation was a priority for the state’s leadership, including the governor, attorney general and House speaker. Intoxicating hemp products with as much as 1,000 mg of THC are being sold in smoke shops—outside of Missouri’s licensed marijuana dispensaries—and they aren’t regulated by any government agency. Missouri lawmakers have failed to pass legislation regulating these products since 2023. The bill comes amidst uncertainty on where the federal government will finally land on regulations for these products. President Donald Trump signed an executive order in December ordering his administration to work with Congress to develop a framework that permits full-spectrum CBD products, which have a trace amount of THC. On Wednesday, the Centers for Medicare & Medicaid Services rolled out an initiative that could cover $500 per year worth of hemp-derived THC of 3mg per serving and CBD products for eligible users. The products under this program would be illegal in Missouri under the bill approved Thursday. This story was first published by Missouri Independent. The post Missouri Lawmakers Pass Bill To Ban Intoxicating Hemp THC Products, Sending It To Governor appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Love to read it,Waiting For More new Update and I Already Read your Recent Post its Great Thanks. landing page copywriting

The atmosphere of the New Delhi Escort Service can be characterized by a smooth and friendly tone, in which elegant figures and friendly communication form the atmosphere that makes it easy to talk and feel a soft feeling of connection.

This is my first visit to your web journal! We are a group of volunteers and new activities in the same specialty. Website gave us helpful data to work. koi toto

Many regular clients appreciate services that are simple, reliable, and well-managed. That is why we focus on maintaining a strong system for Escort Gurgaon bookings. Each profile is verified, and every detail is confirmed before finalizing. This helps customers feel secure and comfortable while choosing our agency for their needs. Our goal is to build trust through consistent and professional service.

They brought refreshing authenticity that made every moment feel significant. Our time with Call Girls Service near by Udman Hotels and Resorts Hotel was both exciting and deeply personal. We explored the charming neighborhood together, shared meaningful conversation, and built a connection that felt effortless and real. This was an experience we would treasure.

Hawaii senators have approved a pair of resolutions calling on Congress to federally legalize marijuana, support state efforts to clear people’s conviction records and take steps to facilitate access to banking services for companies in the cannabis industry. “Even though states have made significant policy changes with respect to cannabis, the federal Controlled Substances Act still classifies cannabis as a Schedule I substance,” the measures advanced by the Senate Judiciary Committee in a 5-0 vote on Thursday say, “which means that medical cannabis dispensaries and other cannabis-related businesses continue to face the prospect of federal seizures, forfeitures, arrests, and other enforcement and prosecution actions.” The legal recreational cannabis industry could generate more than $1 billion in sales in Hawaii by its fifth year of operation, according to a recent state-commissioned study, the resolutions point out. Current medical marijuana businesses in the state “are hampered by their inability to obtain the full spectrum of private banking services under federal law,” the measures sponsored by Sen. Joy San Buenaventura (D) say, adding that “arrests and convictions for cannabis possession remain on record and often impact the ability of a person to obtain housing and employment.” SR58 and SCR64 call on Congress to: (1) Remove cannabis from the federal Controlled Substances Act; (2) Provide support to states that are in the process of clearing defendants’ records of cannabis offenses; and (3) Facilitate access to the full spectrum of banking services for cannabis-related businesses. The legislation as introduced noted that alcohol and tobacco don’t fall under the Controlled Substances Act, “even though the regular use of those substances often leads to physical injuries, psychological and social harm, the onset of chronic and fatal illnesses, and other negative impacts on individual and public health.” But the panel removed that language, with Sen. Karl Rhoads (D), the chair of the committee, saying that the arguments about other substances “seem irrelevant” to the marijuana resolutions. If passed by the legislature, the resolutions will be transmitted to President Donald Trump and Vice President JD Vance, as well as the top Democratic and Republican leaders in the U.S. House of Representatives and Senate and each member of Hawaii’s congressional delegation. Earlier this week, the Senate Health and Human Services Committee adopted separate resolutions calling on the state attorney general and health department to request an exemption from the Drug Enforcement Administration (DEA) stipulating that Hawaii is permitted to run its medical cannabis program without federal interference. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Although Hawaii senators recently approved a bill to legalize low-dose and low-potency marijuana, the legislation didn’t advance through required steps before a key deadline, and so it is dead for the year. A separate marijuana legalization bill that contained provisions making the reform contingent on changes to federal law or the state Constitution, SB 2421, was deferred for action. Both Senate and House panels additionally deferred action on a measure to allow for the sale of certain hemp-derived cannabinoid products. Those actions comes after key House lawmakers signaled that cannabis legalization proposals would not be advancing in the 2026 session, citing a lack of sufficient support in their chamber. Last month, a Hawaii Senate committee separately passed legislation to allow patients to immediately access medical cannabis once their registrations are submitted, instead of having to wait until their cards are delivered as is the case under current law. Meanwhile, a Hawaii House committee last week approved a Senate-passed bill that would create a psychedelics task force responsible for studying and making policy recommendations on providing access to breakthrough therapies such as psilocybin and MDMA. Legislation to allow qualifying patients to access medical marijuana at health facilities is also advancing this session. The post Hawaii Senators Push Congress To Federally Legalize Marijuana And Clear Past Convictions appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

President Donald Trump is requesting that Congress continue to protect state medical marijuana programs from federal interference while also maintaining a policy that has blocked local officials in Washington, D.C. from legalizing recreational cannabis sales. In his Fiscal Year 2027 budget request sent to lawmakers on Friday, the president proposed for the first time to maintain the rider that prevents the Department of Justice from spending any money to “prevent [states] from implementing their own laws that authorize the use, distribution, possession, or cultivation of medical marijuana.” Last year and each year during his first term in office, Trump had requested that Congress delete the medical marijuana provision from annual appropriations legislation. As it appears in the president’s new budget proposal, the medical cannabis rider reads: “SEC. 528. None of the funds made available under this Act to the Department of Justice may be used, with respect to any of the States of Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming, or with respect to the District of Columbia, the Commonwealth of the Northern Mariana Islands, the United States Virgin Islands, Guam, or Puerto Rico, to prevent any of them from implementing their own laws that authorize the use, distribution, possession, or cultivation of medical marijuana.” As is the case with the version most recently enacted into law, the proposed provision would continue to omit Nebraska, which has a medical cannabis law, for reasons that are unknown. President Joe Biden had consistently proposed to continue the medical cannabis rider in his budget requests—though President Barack Obama, like Trump, had sought to delete it. Congress has the final say on appropriations legislation language, however, and has not followed through on any president’s request to delete the medical marijuana protection since it was first enacted in 2014—though lawmakers have also declined to expand the protections to cover state recreational marijuana programs. After signing prior appropriations bills into law that included the medical cannabis protection in contravention of his request to delete it, Trump on three occasions during his first term issued statements that specifically said his administration “will treat this provision consistent with the President’s constitutional responsibility to faithfully execute the laws of the United States”— implying he was reserving his right to ignore the rider. Now, however, he is requesting that Congress continue the state medical cannabis protection policy, a move that comes months after the president issued an executive order directing the attorney general to complete the process of moving marijuana from Schedule I of the Controlled Substances Act to Schedule III. Meanwhile, Trump is also proposing to continue a separate provision that prevents District of Columbia officials from legalizing and regulating adult-use marijuana sales in the nation’s capital. The policy, which has been championed by Rep. Andy Harris (R-MD), appears in Trump’s budget request as follows: “SEC. 809. (a) None of the Federal funds contained in this Act may be used to enact or carry out any law, rule, or regulation to legalize or otherwise reduce penalties associated with the possession, use, or distribution of any schedule I substance under the Controlled Substances Act (21 U.S.C. 801 et seq.) or any tetrahydrocannabinols derivative. (b) No funds available for obligation or expenditure by the District of Columbia government under any authority may be used to enact any law, rule, or regulation to legalize or otherwise reduce penalties associated with the possession, use, or distribution of any schedule I substance under the Controlled Substances Act (21 U.S.C. 801 et seq.) or any tetrahydrocannabinols derivative for recreational purposes.” While Congress has continually blocked D.C. from legalizing recreational marijuana sales with the annually approved rider, local officials have worked to expand access through the existing medical cannabis market by, for example, by allowing residents and even visiting tourists to self-certify without the need for doctors’ recommendations. This week, Mayor Muriel Bowser (D) proposed local legislation to allow medical marijuana companies to partner with local breweries and distilleries to produce cannabis-infused, alcohol-free drinks. It is possible that moving marijuana out of Schedule I, as the administration is still considering doing, would give D.C. a workaround to the provision as it is drafted, but some observers have raised questions about the implications of the rider’s use of the term “tetrahydrocannabinols derivative,” which is not defined in federal law. The president’s budget additionally proposes to continue a rider protecting state hemp programs from federal interference. The hemp provision reads: “SEC. [737]724. None of the funds made available by this Act or any other Act may be used— (1) in contravention of section 7606 of the Agricultural Act of 2014 (7 U.S.C. 5940), subtitle G of the Agricultural Marketing Act of 1946, or section 10114 of the Agriculture Improvement Act of 2018; or (2) to prohibit the transportation, processing, sale, or use of hemp, or seeds of such plant, that is grown or cultivated in accordance with section 7606 of the Agricultural Act of 2014 or subtitle G of the Agricultural Marketing Act of 1946, within or outside the State in which the hemp is grown or cultivated.” Finally, due to the way that presidents’ budget requests are formatted depicting proposed changes to previously enacted spending legislation, Trump’s new proposal also contains language showing the removal of provisions to redefine and recriminalize certain hemp THC products that he signed into law last year and that are set to take effect this November. Because that legislation changed federal law on an ongoing basis, it does not need to be reenacted annually in the way that the policy riders do—so Trump’s budget deletes the provisions from being duplicatively included in FY2027 appropriations legislation. The president’s budget request now heads to Congress, where lawmakers will craft a series of spending bills to actually fund the government with provisions that may differ from the president’s proposals. The post Trump Proposes To Keep Protecting State Medical Marijuana Laws From Federal Interference While Blocking DC From Legalizing Recreational Sales appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Federal officials have finalized a rule that will allow coverage of some hemp products as specialized, non-primarily health-related benefits through Medicare Advantage (MA) plans. In a filing set to be published in the Federal Register on Monday, the Centers for Medicare & Medicaid Services (CMS) is clarifying that certain cannabis products that are legal under both state and federal laws are eligible to be reimbursed under the Special Supplemental Benefits for the Chronically Ill (SSBCI) program. Under a previous update to the program adopted in April 2025, CMS determined that all cannabis products are not eligible for coverage under certain health plans for chronically ill patients. But the new rule only prohibits coverage of “cannabis products that are illegal under applicable State or Federal law.” The development is separate from a program CMS launched this week to allow Medicare coverage of hemp-derived CBD and THC products that meet certain requirements, with this one instead focusing on allowing MA organizations to offer hulled hemp seed, hemp seed protein powder and hemp seed oil as covered benefits. Coverage under new policy is contingent on the Food and Drug Administration’s (FDA) determination that the products are generally recognized as safe (GRAS) and that they meet a standard on there being a “reasonable expectation of improving or maintaining the health or overall function” for SSBCI benefits. “For example, there is evidence that hemp seed protein powder may offer nutritional benefits,” CMS said. The agency’s filing notes that under the 2018 Farm Bill signed by President Donald Trump during his first term, hemp products with less than 0.3 percent delta-9 THC on a dry weight basis are legal under federal law but that a more recently approved change that’s set to take effect this November will recriminalize any products with more than 0.4 milligrams of total THC per container. “Therefore, this regulation will allow MA organizations to offer hulled hemp seed, hemp seed protein powder, and hemp seed oil, consistent with FDA’s review of the GRAS notices, as SSBCI to qualifying enrollees, to the extent otherwise appropriate as SSBCI and under federal and applicable state law. Additionally, at the time of this rulemaking, any cannabis product with a delta-9 THC content above the 0.3 percent threshold is still considered marijuana, remains a Schedule I controlled substance, and therefore is illegal under federal law and would be subject to CMS’s prohibition. Barring subsequent legal changes, any product that does not comply with the amended definition of hemp after the November 12th, 2026 effective date will be a Schedule I controlled substance and therefore will be illegal under federal law and subject to CMS’s prohibition.” The new rule, which was first proposed in November and is now being finalized, also clarifies that state laws that are more strict than federal law could narrow what types of products are eligible for coverage by MA organizations in their jurisdictions. “The amended language also clarifies that MA organizations remain prohibited from covering any cannabis product, including any hemp-derived cannabis product, that is illegal under state law within their service area regardless of the product’s federal legal status,” it says. The filing also contemplates the possible expansion of the types of products that could be able to be covered in the future. “At the time of this rulemaking, there are only three products that are permissible under applicable state and federal law and therefore may be covered as SSBCI. Those products are hulled hemp seed, hemp seed protein powder, and hemp seed oil,” it says. “However, should additional products become allowable as the law continues to evolve, this regulation would allow MA plans in a subsequent plan year the option to increase their offerings without requiring additional rulemaking from CMS.” “Therefore, should other cannabis-derived products become allowable as SSBCI due to changes in state or federal law, MA plans must wait until their next bid submission for the following plan year to add these items to their list of covered SSBCI,” the agency noted. CMS also responded to a public comment about the potential impact of federal marijuana rescheduling under a still-ongoing process that Trump directed to be completed “in the most expeditious manner” in December. “Should cannabis be rescheduled to Schedule III, this would change its status under the Controlled Substance Act,” CMS said. “However, rescheduling alone would not automatically make cannabis products allowable SSBCI unless the relevant products also meet other applicable State and Federal laws, including the” Federal Food, Drug, and Cosmetic Act. The separate CMS hemp product coverage initiative rolled out this week is being challenged in a lawsuit filed by a coalition of anti-marijuana organizations. A federal judge denied their motion for a temporary restraining order to halt it from launching, but scheduled a hearing for April 20 on their separate request for a preliminary injunction. Meanwhile, the White House Office of Management and Budget is holding a series of meetings this week and next week about an FDA CBD products enforcement policy. Also this week, FDA issued guidance making clear that it does not intend to interfere with implementation of the Medicare hemp-derived products coverage plan. The post Feds Finalize New Rule Allowing Some Hemp Products As Medicare Advantage Benefits appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Bhopal Call girls have a soft, inviting way of making moments feel personal. There’s an easy warmth in how they speak and listen, creating a connection that feels natural. Bhopal Call girls don’t rush things—Bhopal Call girls let attraction build slowly, through conversation and subtle chemistry. That calm charm mixed with quiet confidence makes the experience feel intimate. You feel noticed, appreciated, and drawn in without effort. It’s the kind of presence that lingers in your thoughts, leaving you wanting more time together.

A governor-appointed cannabis commission in North Carolina has issued an interim report after holding months of meetings focused on the issue. The group is recommending that the state move away from a criminalization-based approach to cannabis and toward a system of “robust” regulations that provide for adults’ legal access to THC products. The North Carolina Advisory Council on Cannabis, which Gov. Josh Stein (D) convened last year, says in the new document approved on Thursday that the current “absence of regulation for North Carolina’s intoxicating cannabis market raises numerous concerns,” noting that hemp products are readily available yet largely unregulated and that marijuana remains prohibited altogether in the state, even for medical use. “North Carolina’s intoxicating cannabis market currently exists in a dangerous policy gap that is neither true prohibition nor meaningful regulation.” “Compared to regulated marijuana frameworks in other states, this environment presents identifiable risks,” the report says. “While some operators voluntarily implement consumer protection protocols, these safeguards are not required under state law.” Stein, for his part, thanked the group for its “expertise, hard work, and thoughtful deliberation” in a press release and reiterated his support for legalizing marijuana. “Last year, I charged this group with developing a comprehensive solution to the unregulated sale of cannabis that is grounded in public health and public safety, with a special focus on keeping young people safe,” the governor said. “This report provides the General Assembly with guidance and makes clear that a well-regulated market, including both oversight and enforcement authority, is a safer market for our state.” “Our state’s unregulated cannabis market today is the Wild West and is crying for order,” he said. “Let’s get this right. Let’s protect our kids and create a safe, legal, and well-regulated market for adults.” The council’s report notes that North Carolina is “at a pivotal moment,” given that the state is one of only 10 that does not allow legal and regulated marijuana access for either recreational or medical use. “In the absence of a recognized, regulated marijuana market, North Carolina has one of the largest illicit marijuana markets in the United States, with an estimated $3 billion spent on illegal marijuana in 2022, ranking second in the nation. Additionally, North Carolina’s current market for intoxicating hemp-derived cannabinoid products is robust. These products have proliferated across the state through retail storefronts, vape shops, convenience stores, and online vendors. Intoxicating hemp-derived cannabinoid products, often marketed as legal alternatives to marijuana, are being sold in an environment without any uniform standards for manufacturing, testing, labeling, packaging, or age verification, and absent any enforcement or oversight authority.” Under the prohibition approach that the state currently has, the report notes that there is an absence of age restrictions, packaging rules, purchase limits, licensing requirements, zoning guidelines and supply chain oversight. There is also a lack of tax revenue that can be used to address any health and safety concerns associated with marijuana use and commerce. Looking ahead, the interim report recommends that rather than construct separate frameworks for hemp and marijuana, the state should enact molecule-based regulation focused on THC itself, saying that “the plant source is irrelevant and should not drive different treatment when the intoxicating compound is the same.” It also suggests that when choosing how to regulate THC and cannabis, North Carolina should enact “an adult access market with protections for medical consumers.” The panel, however, “does not view a medical-only program as an effective interim step or compromise solution,” and the state should proceed to adult-use access immediately while considering the “availability of medical-consumer protections” as “an important component of a broader regulatory structure.” “Under this framework, adults would be permitted to legally purchase, possess, and use cannabis through state-licensed retail outlets. An adult-use market provides the state with a full regulatory framework and the tools necessary to manage it responsibly. The recommended system also incorporates rigorous medical-grade safeguards, including low-THC product options, comprehensive testing standards, expanded product warnings, recall authority, and access to qualified medical consultation, among others. Importantly, this model would provide the most robust regulatory framework for the state, providing the oversight tools necessary to manage the industry responsibly while generating state revenue. It allows for structured licensing fees and tax revenue to support oversight, the development of clear and enforceable rules, sustained public health messaging grounded in prevention and education, and dedicated resources for compliance and enforcement. This recommendation provides a structure to reign in the rampant hemp market that exists today, while providing necessary guardrails for both public safety and public health.” “Of all possible regulation models, an adult access model would bring the most revenue to the state, which could support public health education campaigns and enforcement efforts,” the advisory council recommended. The report also noted problems that could be caused by the fact that the state is lagging behind its neighbors that are moving ahead with enacting marijuana policy reforms. “If surrounding states adopt regulated cannabis programs while North Carolina does not, the state could effectively become a prohibition jurisdiction situated among regulated markets, a dynamic that may complicate enforcement and influence the flow of products and consumers across state lines,” the report said. Because the council only has the ability to recommend policies and not to actually enact them, members put the onus on state lawmakers to do so. “Ultimately, the authority to bring order to the unregulated, unsafe cannabis market rests with the General Assembly,” the report notes. “The question before policymakers—and this Council—is not whether intoxicating cannabinoid products will exist in the marketplace in North Carolina. They already do. Rather, the question is whether the General Assembly will allow intoxicating products to continue to be sold without enforceable state standards, or whether it will establish a regulatory system designed to protect public health and public safety.” The advisory council was formed after Stein issued an executive order last year, and is comprised of legislators, law enforcement officials, agriculture industry stakeholders, health experts, tribal representatives, advocates and others charged with exploring possible regulatory models for adult-use marijuana and hemp. The governor’s order said there’s a need for reform because the “current lack of regulation, including age, potency, and purity limitations, poses a threat to all North Carolinians, particularly our youth.” And “rather than allowing this unsafe and unregulated market to continue, smart and balanced regulation presents an opportunity not only to protect the health and well-being of our people, but also to generate revenue that can benefit our state.” Members are tasked with developing and submitting initial recommendations on a “comprehensive cannabis policy, including any proposed legislation,” with a final report due by December 31 of this year. The interim report approved this week says that the final document “will incorporate continued stakeholder engagement, data analysis, and policy development and will present a research-based and data-driven comprehensive framework intended to bring structure, accountability, and public confidence to a future North Carolina cannabis marketplace.” In the meantime, the council is continuing its work with new subcommittees focused on regulatory structure, enforcement and criminal justice reform and revenue and federal compliance. During his time as the state’s attorney general, Stein led a separate task force under then-Gov. Roy Cooper (D) that examined racial injustice issues and ultimately recommended decriminalizing marijuana and studying broader legalization in response to racially disparate enforcement trends. In recent legislative sessions, multiple limited medical marijuana legalization bills advanced through the Senate, only to stall out in the House. Meanwhile, a tribe in North Carolina, the Eastern Band of Cherokee Indians, launched the state’s first marijuana dispensary in 2024—despite the protests of certain Republican congressional lawmakers. Photo courtesy of Philip Steffan. The post North Carolina Governor Steps Up Push For Marijuana Legalization As State Commission Issues New Report appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

FBI agents received specific guidance prohibiting them investing in marijuana companies—but not necessarily those that make hemp or CBD products—according to a 2022 memo that the agency released last week for reasons that are unclear. The allowance for hemp investments and work contains an exception blocking involvement with companies whose packaging “promotes marijuana”—including any depiction of a cannabis leaf, however. The now-unclassified policy directive also details restrictions for agents who work or volunteer outside their roles at FBI, stipulating that they could not take employment opportunities “with any company cultivating, processing, or distributing marijuana, regardless of the legal status of marijuana under local, state, tribal or foreign law.” For both the investment and employment guidance, there are carve-outs—with certain caveats—for products and businesses that deal with hemp or the non-intoxicating cannabinoid CBD, which were federally legalized under the 2018 Farm Bill during President Donald Trump’s first term. The document states that FBI workers can “invest, without restriction, in companies that maintain a financial interest in the CBD industry” unless that interest involves CBD products containing more than 0.3 percent THC by dry weight, which is how federal law currently distinguishes between illegal marijuana and legal hemp. Agents also can’t invest in CBD businesses or products that promote marijuana for medical or recreational purposes. “The determination of whether or not a product promotes marijuana depends on various circumstances, but may be indicated by the product (or advertising for the product) displaying words, images, or associations with marijuana. For example, a product depicting a marijuana leaf on its label is considered promotion of marijuana, and would therefore be impermissible. Employees must consult their [chief division counsel] or the [Office of Integrity and Compliance] to determine whether the company is promoting marijuana.” Under the policy directive, FBI workers are also “prohibited from engaging in outside employment (or any other outside activity [such as volunteering]) with any company cultivating, processing, or distributing marijuana, regardless of the legal status of marijuana under local, state, tribal, or foreign law.” FBI treats marijuana differently from hemp-derived CBD given its legalization under federal law. Workers who make a request to work or volunteer at a business associated with the manufacturing or distribution of cannabidiol products would need to use a specific reporting tool to obtain approval. “Approving authorities must consider such requests on a case-by-case basis and must deny any request to engage in outside employment (or an outside activity) that could create an appearance of violating the law or violating ethical standards, or is otherwise incompatible with maintaining a security clearance. For example, an FBI employee’s request to work for or volunteer with a company producing a drink that contains 0.3 percent or less CBD, but depicts a marijuana leaf on the label, must be denied due to the appearance of promoting illegal drug use.” That component of the directive appears to include a key error by referencing drinks containing up to 0.3 percent of CBD. That trace percentage is typically associated with THC, not CBD, when talking about federal hemp and marijuana policy. Hemp drinks with more than 0.3 percent CBD would typically be considered federally legal, unless they also happened to contain more than 0.3 percent THC. Marijuana Moment reached out to FBI for comment, but a representative was not immediately available. FBI also said in the guidance that workers’ requests to “work at a grocery store that sells products containing CBD (amongst other unrelated products) may be approved if all other applicable criteria” are met. Workers who violate the policy “may be subject to disciplinary or administrative action, including suspension or revocation of security clearance,” the agency said. Again, it’s unclear why FBI declassified this guidance at this point in time, or whether it remains in effect as written. But it’s possible it may need to be revisited in the near future given that the federal definition of hemp and its derivatives are set to become significantly more restrictive, effectively banning all consumable cannabinoid products, under a law Trump signed last year that takes effect in November. Also in 2022, meanwhile, FBI announced that the recent use of marijuana—and even CBD—automatically disqualified people from working at the federal agency. People interested in joining FBI must have abstained from consuming cannabinoids, including the non-intoxicating kind, for at least a year before submitting an application. That guidance didn’t include mention of another marijuana employment rule that FBI previously instituted that rendered applicants ineligible for a job at the agency if they’ve used marijuana more than 24 times after turning 18. In general, FBI’s gradual loosening of its marijuana employment policies has been interpreted as a more practical decision, rather one that necessarily reflects shifting opinions on cannabis within the agency. Then-FBI Director James Comey suggested in 2014 that he wanted to loosen the agency’s employment policies as it concerns marijuana, as potential skilled workers were being passed over due to the requirement. The post FBI Says Agents Can Invest And Work In Hemp Companies But Not Marijuana Industry, Newly Declassified Memo Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

FDA CBD memo; MA anti-marijuana initiative faces lawsuit; DC mayor’s cannabis drinks plan; TX medical marijuana licenses; VA prepares for legal sales Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Free to read (but not free to produce)! We’re proud of our newsletter and the reporting we publish at Marijuana Moment, and we’re happy to provide it for free. But it takes a lot of work and resources to make this happen. If you value Marijuana Moment, invest in our success on Patreon so we can expand our coverage and more readers can benefit: https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW Food and Drug Administration Commissioner Marty Makary issued a guidance memo saying the agency “does not intend to enforce” certain federal laws against hemp-derived CBD products covered under a new Medicare initiative if they meet specific requirements. If President Donald Trump replaces outgoing Attorney General Pam Bondi with Lee Zeldin, as he is reportedly considering, it could impact the marijuana rescheduling process—as Zeldin has a mixed record on cannabis as a former lawmaker. A coalition of Massachusetts marijuana businesses filed a lawsuit to keep a measure to roll back recreational cannabis legalization off the November ballot, claiming it violates the state Constitution. Washington, D.C. Mayor Muriel Bowser (D) proposed new legislation to allow medical marijuana companies to partner with local breweries and distilleries to produce cannabis-infused drinks for sale in the nation’s capital. The Virginia Cannabis Control Authority opened applications for about a dozen new regulatory and compliance roles that will help oversee recreational marijuana sales under a legalization bill that Gov. Abigail Spanberger (D) is set to act on this month. The Maryland House of Delegates passed a bill to let firefighters and rescue workers use medical cannabis off duty, with the sponsor saying first responders “should not be punished for seeking legal, medically prescribed relief.” The Texas Department of Public Safety conditionally approved three new medical cannabis business licenses as part of an expansion of patient access to marijuana under a new law passed by lawmakers and signed by the governor last year. / FEDERAL The Drug Enforcement Administration promoted a video about “using AI to combat the opioid crisis.” / STATES New York regulators approved changes to rules on cannabis showcase events as well as additional marijuana business licenses. Colorado regulators posted updated draft psychedelics rules. Pennsylvania regulators published a list of approved hemp compliance testing laboratories. The New Jersey Cannabis Regulatory Commission published a post touting the fifth anniversary of the agency. Minnesota regulators sent a newsletter with updates on various cannabis issues. Utah regulators sent an update on the medical cannabis program. The Massachusetts Cannabis Social Equity Advisory Board will meet on Friday. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / LOCAL The Minneapolis, Minnesota City Council will consider a proposal to decriminalize possession of drug paraphernalia on Tuesday. / INTERNATIONAL Tasmania, Australia lawmakers launched a petition calling for a formal inquiry into the state’s cannabis laws. / SCIENCE & HEALTH A study’s findings “support the use of oral full-spectrum Cannabis oil as a safe and effective complementary therapy for improving pain and quality of life in dogs with” chronic osteoarthritis. A study found that “administration of up to eight doses of psilocybin in a clinical research setting appears to be safe and potentially effective for patients with” obsessive-compulsive disorder. / BUSINESS Vireo Growth Inc. enacted a management services agreement with PharmaCann Inc. allowing it to manage certain Colorado assets through the closing of an acquisition. RYTHM, Inc. announced amendments to its existing trademark and recipe license agreements with a subsidiary of Green Thumb Industries Inc. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post How could new attorney general impact cannabis rescheduling? (Newsletter: April 3, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net